



Polyhydroxylated pyrrolidines. Part 2: Highly stereoselective synthesis of partially protected DMDP derivatives from D-fructose

Isidoro Izquierdo,* María T. Plaza and Francisco Franco

Department of Medicinal and Organic Chemistry, Faculty of Pharmacy, University of Granada, 18071 Granada, Spain

Received 23 May 2002; accepted 8 July 2002

Abstract—The readily available 3,4-di-*O*-benzyl-1,2-*O*-isopropylidene-β-D-fructopyranose **2** was straightforwardly transformed into 5-azido-3,4-di-*O*-benzyl-5-deoxy-1,2-*O*-isopropylidene-β-D-fructopyranose **4**, after treatment under modified Garegg's conditions followed by reaction of the resulting 3,4-di-*O*-benzyl-5-deoxy-5-iodo-1,2-*O*-isopropylidene-α-L-sorbopyranose **3** with sodium azide in DMF. Cleavage of the acetonide of **4** to afford **6** followed by regioselective *O*-*tert*-butyldiphenylsilylation at C(1)OH afforded **7**. Hydrogenation of **7** proceeded with high stereoselectivity yielding 3,4-di-*O*-benzyl-1-*O*-*tert*-butyldiphenylsilyl-2,5-dideoxy-2,5-imino-D-mannitol **1**, confirmed by its *O*-desilylation to **8**. Compound **1** was subjected to different *N*-protection reactions to afford the corresponding *N*-allyl (**1a**), *N*-benzyl (**1b**), and *N*-*tert*-butyloxycarbonyl (**1c**) derivatives. © 2002 Elsevier Science Ltd. All rights reserved.

1. Introduction

In two previous papers, we reported on the highly stereoselective synthesis, starting from the cheap and commercially available D-fructose, of appropriately protected polyhydroxypyrrolidines, such as those derived from 2,5-dideoxy-2,5-imino-D-glucitol (DGDP),¹ and later on the use of DGDP as an excellent chiral key intermediate for the synthesis² of two isomeric analogues [7*a*-*epi*-hyacinthacine A₂ (7-deoxyalexine) and 5,7*a*-*diepi*-hyacinthacine A₃] of the recently isolated³ hyacinthacines, which are potent glycosidase inhibitors.

Continuing with these efforts, we describe herein the highly stereoselective synthesis, starting from the same hexulose, of those isomeric and partially protected polyhydroxypyrrolidines derived from the natural glycosidase inhibitor, 2,5-dideoxy-2,5-imino-D-mannitol (DMDP).⁴

Retrosynthetic analysis (Fig. 1) shows the potential of **1** in the preparation of polyhydroxylated pyrrolidines (australine and hyacinthacines A₂ and A₃), where it can be clearly seen that an adequately protected DMDP **1** is an excellent chiral starting material for the synthesis of such target molecules. Thus, chain extension at C(5')




Figure 1. Retrosynthesis of polyhydroxylated pyrrolidines.

* Corresponding author. E-mail: isidoro@platon.ugr.es

(originally C(6) of D-fructose) by a suitably functionalized two carbon fragment, followed by further cyclization, could lead to pyrrolizidines which stereochemistry at C(7a) belonging to that of the australine series.

2. Results and discussion

According to Scheme 1, the reaction of 3,4-di-*O*-benzyl-1,2-*O*-isopropylidene- β -D-fructopyranose¹ **2** under modified Garreg's conditions,⁵ caused the slow substitution of the C(5) hydroxyl group, with concomitant inversion of configuration, to afford the corresponding 5-deoxy-5-iodo- α -L-*sorbo* derivative **3**, which had the same analytical and spectroscopic data to those previously reported.⁶ Treatment of **3** with sodium azide in *N,N*-DMF effected S_N2 substitution to yield 5-azido-2,3-di-*O*-benzyl-5-deoxy-1,2-*O*-isopropylidene- β -D-fructopyranose **4**.⁶

In order to shorten the synthesis, an attempt to transform **2**→**4** in a one-pot reaction, by treatment of the former with CBr₄/Ph₃P/NaN₃/DMF/110°C,⁷ resulted in the isolation of **5**, the 5-bromo-5-deoxy analogue of **3** and **4**, both in low yield.

Cleavage of the acetonide group of **4** by treatment with 70% aqueous trifluoroacetic acid afforded 5-azido-2,3-di-*O*-benzyl-5-deoxy- β -D-fructopyranose **6**. Reaction of **6** with *tert*-butyldiphenylchlorosilane took place selectively at the primary hydroxyl group affording the corresponding 1-*O*-silylated derivative **7**. Compounds **6** and **7** existed as only one anomer (¹³C NMR data).

Catalytic (Raney nickel) hydrogenation of **7** caused reduction of the 5-azido group to the corresponding 5-amino function which internally condensed with the carbonyl group at C(2) to produce a Δ^2 -pyrroline (**A**, not isolated but detected by TLC) which is finally hydrogenated to the expected partially *O*-protected pyrrolidine **1**. The (*R*)-configuration of the new C(2) stereogenic center in **1**, could be easily determined through its *O*-desilylation to **8**, whose ¹H and ¹³C NMR spectra were consistent with its C₂-symmetry (Scheme 2).

The high stereoselectivity found in the hydrogenation of **7**, where **1** was the only pyrrolidine detected and isolated, merits comment. The formation of **1** could be explained, according to our results¹ and those of other authors,⁸ by the addition of hydrogen to the same β -face occupied by the substituent next to the N=C bond, giving a product with the C(2)- and C(3)-substituents in a *trans*-disposition (see Fig. 2).






Figure 2. Proposed stereochemistry for the hydrogenation pathway of intermediate Δ^2 -pyrroline (**A**).



Scheme 1. Synthesis of protected 5-azido-5-deoxy-D-fructose derivative **4**. *Reagents and conditions:* (i) Ph₃P/I₂/imidazole/DMF/ Δ ; (ii) NaN₃/DMF/ Δ ; (iii) CBr₄/Ph₃P/NaN₃/DMF/ Δ .



Scheme 2. Synthesis of protected pyrrolidine **1**. *Reagents and conditions:* (i) 70% aq. TFAA; (ii) TBBDPSCl/DMF/imidazole; (iii) Raney-Ni/H₂; (iv) AllBr/K₂CO₃/Me₂CO/rt; (iv) BnBr/K₂CO₃/Me₂CO/rt; (iv) (*t*-BuOCO)₂O/TEA/Cl₂CH₂; (v) *t*-Bu₄N⁺F⁻·3H₂O/THF.

Table 1. ¹H NMR chemical shifts (δ) with multiplicities and *J* (Hz) values for compounds **1**, **1a-c**, and **5-8**

Compd	H-1	H-1'	H-2	H-2'a	H-2'b	H-3	H-4	H-5	H-5'a	H-5'b	H-6	H-6'	PhCH ₂ ^a	Me ₃ C
1 ^b	–	–	3.28q, <i>J</i> _{2,3} =4.9	3.80dd, <i>J</i> _{2'a,2'b} =10.7, <i>J</i> _{2,2'a} =4.7	3.76dd, <i>J</i> _{2,2'b} =4.9	4.00bt	3.88t, <i>J</i> _{3,4} =3.9, <i>J</i> _{4,5} =3.9	3.35bq	3.59dd, <i>J</i> _{5,5'a} =5.0, <i>J</i> _{5,5'b} =6.7	3.56dd, <i>J</i> _{5,5'b} =6.7	–	–	3.54s, 4.46s	1.07
1a ^c	–	–	3.47dd, <i>J</i> _{2,2'b} =8.5	3.85dd, <i>J</i> _{2,2'a} =4.5, <i>J</i> _{2'a,2'b} =10.1	3.75t	4.18s	4.07d, <i>J</i> _{4,5} =3.8	3.12bt, <i>J</i> _{5,5'a} =3.3	3.74dd	3.60bd, <i>J</i> _{5'a,5'b} =11.3	–	–	4.59d and 4.53d, <i>J</i> =12.1, 4.58d and 4.51d, <i>J</i> =11.8	1.05
1b ^d	–	–	3.39bt	3.75m	3.63dd, <i>J</i> _{2,2'b} =6.5, <i>J</i> _{2'a,2'b} =11.0	4.24s	4.14bd, <i>J</i> _{4,5} =4.8	3.24bt	3.85–3.77m	–	–	–	4.61d and 4.48d, <i>J</i> =11.8, 4.58d and 4.52d, <i>J</i> =13.5, 3.86d and 3.73d, <i>J</i> =14.2	1.03
1c	–	–	4.15–4.06m, 3.98dt, 3.92–3.80m, and 3.72t	4.40s	4.40s	4.15–4.06m, 3.98dt, 3.92–3.80m, and 3.72t	–	–	–	–	–	–	4.66d and 4.59d, <i>J</i> =12.2, 4.51s 4.98d and 4.83d, <i>J</i> =10.2, 4.95d and 4.64d, <i>J</i> =11.4	1.30, 1.06
5 ^e	3.90d, <i>J</i> =8.6	3.82d	–	–	–	4.00–3.84m	3.39m	–	–	–	4.00–3.84m	–	–	–
6	3.56d, <i>J</i> =11.53	3.46d	–	–	–	3.85d, <i>J</i> _{3,4} =9.5	4.10dd, <i>J</i> _{4,5} =3.7	3.90m	–	–	3.97dd, <i>J</i> _{5,6} =1.4, <i>J</i> _{6,6'} =13.5	3.66dd, <i>J</i> _{5,6'} =1.8	4.94d and 4.67d, <i>J</i> =11.1, 4.77d and 4.73d, <i>J</i> =11.6	–
7	3.69d, <i>J</i> =10.1	3.56d	–	–	–	3.79d, <i>J</i> _{3,4} =9.5	4.17dd, <i>J</i> _{4,5} =3.6	3.94m	–	–	4.93bd, <i>J</i> _{6,6'} =12.4	3.71bd	4.90d and 4.56d, <i>J</i> =11.1, 4.79d and 4.76d, <i>J</i> =12.0	1.07
8 ^f	–	–	3.32m	3.64dd, <i>J</i> _{2,2'a} =4.3, <i>J</i> _{2'a,2'b} =11.3	3.59dd, <i>J</i> _{2,2'b} =6.7	3.81bd, <i>J</i> _{2,3} =3.8	3.81bd, <i>J</i> _{4,5} =3.8	3.32m	3.64dd, <i>J</i> _{5,5'a} =4.3, <i>J</i> _{5'a,5'b} =11.3	3.59dd, <i>J</i> _{5,5'b} =6.7	–	–	4.54s	–

^a Signals for phenyl groups are not included.^b Signal for OH at 2.82 ppm.^c Signals for allyl group at 5.78dddd, 5.02dd, 5.00bd, 3.29dd and 3.20dd; signal for OH at 2.82 ppm.^d Signal for OH at 2.86 ppm.^e Signals for Me₃C at 1.51 and 1.45 ppm.^f Signal for OH and NH at 3.21 ppm.

Table 2. ^{13}C NMR chemical shifts (δ) for compounds **1**, **1a–c**, and **5–8**

Compd	C-1	C-2	C-2'	C-3	C-4	C-5	C-5'	C-6	PhCH ₂ ^a	Me ₃ C	Me ₃ C	Me ₂ C	Me ₂ C
1	–	63.31 ^b	62.96 ^c	85.77 ^d	85.10 ^d	63.23 ^b	62.10 ^e	–	72.10, 72.01	27.00	19.38	–	–
1a	–	67.21	60.97	83.36	86.11	67.95	59.96	–	71.89, 71.35	26.92	19.26	–	–
1b	–	66.35	61.31	83.45	86.07	68.01	60.04	–	71.91, 71.36, 51.01	26.90	19.21	–	–
1c^e	–	65.47	64.78	81.66	84.21	66.69	62.01	–	71.53, 71.43	28.31, 26.92	19.31	–	–
5	71.55	105.48	–	83.84 ^b	79.73 ^b	48.16	–	64.00	76.17, 75.52	–	–	112.56	26.19, 26.16
6	65.68	97.96	–	78.93 ^b	75.38 ^b	59.92	–	61.51	75.74, 72.68	–	–	–	–
7	65.89	98.21	–	79.07 ^b	75.24 ^b	60.22	–	61.17	75.66, 72.72	26.86	19.34	–	–
8	–	63.51	62.30	85.48	85.48	63.51	62.30	–	72.07	–	–	–	–

^a Signals for the phenyl groups are not included.

^b Interchangeable assignments.

^c Interchangeable assignments.

^d Interchangeable assignments.

^e Signal for CO at 155.67 ppm.

3. Experimental

3.1. General

Melting points were determined with a Gallenkamp apparatus and are uncorrected. Solutions were dried over MgSO₄ before concentration under reduced pressure. The ^1H and ^{13}C NMR spectra were recorded with Bruker AMX-300, AM-300, and ARX-400 spectrometers for solutions in CDCl₃ (internal Me₄Si). IR spectra were recorded with a Perkin–Elmer 782 instrument and mass spectra with a Micromass Mod. Platform II and Autospec-Q mass spectrometers. Optical rotations were measured for solutions in CHCl₃ (1 dm tube) with a Jasco DIP-370 polarimeter. TLC was performed on precoated E. Merck silica gel 60 F₂₅₄ aluminum sheets with detection by employing a mixture of 10% ammonium molybdate (w/v) in 10% aqueous sulphuric acid containing 0.8% cerium sulphate (w/v) and heating. Column chromatography was performed on silica gel (E. Merck, 7734). The no crystalline compounds, for which elemental analyses were not obtained, were shown to be homogeneous by chromatography and characterized by NMR spectroscopy and FAB-HRMS with thioglycerol matrix.

3.2. 3,4-Di-*O*-benzyl-5-deoxy-5-iodo-1,2-*O*-isopropylidene- α -L-sorbopyranose **3**

To a solution of triphenylphosphine (6.43 g, 24.55 mmol), imidazole (3.24 g, 49.08 mmol) and iodine (6.22 g, 24.55 mmol) in dry DMF (50 mL) was added 3,4-di-*O*-benzyl-1,2-*O*-isopropylidene- β -D-fructopyranose¹ **2** (4.91 g, 12.27 mmol) and the mixture heated at 110°C for 2 days. TLC (2:1 ether–hexane) then revealed a less polar product. The solvent was evaporated under vacuum and the residue dissolved in ether (50 mL) and washed with 10% aqueous sodium thiosulphate and

water, then concentrated. Column chromatography (2:3 ether–hexane) afforded crystalline **3** (3 g, 48%); mp 93–94°C (lit.⁶ mp 85–87°C). Compound **3** had the same optical and spectroscopy data to those previously reported.⁶

3.3. 5-Azido-3,4-di-*O*-benzyl-5-deoxy-1,2-*O*-isopropylidene- β -D-fructopyranose **4**

A stirred solution of **3** (2.93 g, 5.7 mmol) and sodium azide (1.52 g, 23.4 mmol) in dry DMF (50 mL) was heated at 100°C for 5 days. TLC (1:1 ether–hexane) then revealed a slightly more polar compound. The mixture was concentrated to a residue that was dissolved in ether (40 mL), washed with brine and concentrated. Column chromatography (1:4 ether–hexane) of the residue afforded **4** (2.05 g, 85%), which had the same optical and spectroscopy data to those previously reported.⁶

3.4. 3,4-Di-*O*-benzyl-5-bromo-5-deoxy-1,2-*O*-isopropylidene- α -L-sorbopyranose **5** and **4**

To a stirred solution of **2** (1.7 g, 4.25 mmol) in dry DMF (30 mL) were added triphenylphosphine (1.67 g, 6.38 mmol), carbon tetrabromide (2.12 g, 6.38 mmol), and sodium azide (0.83 g, 12.8 mmol). The mixture was heated at 110°C overnight. TLC (2:1 ether–hexane) then revealed a complex mixture. The solvent was eliminated and the residue dissolved in dichloromethane (30 mL) and washed with water, then concentrated. Column chromatography (1:4 ether–hexane→ether) afforded first crystalline **5** (150 mg); mp 77–80°C; $[\alpha]_{\text{D}}^{24} -16^\circ$ (*c* 1.1). For NMR data, see Tables 1 and 2. Anal. calcd for C₂₃H₂₇BrO₅: C, 59.61; H, 5.87. Found: C, 60.11; H, 5.99%. Eluted second was **4** (150 mg).

3.5. 5-Azido-3,4-di-*O*-benzyl-5-deoxy- β -D-fructopyranose **6**

A solution of **4** (570 mg, 1.34 mmol) in 70% aqueous trifluoroacetic acid (2 mL) was kept at room temperature for 5 h. TLC (2:1 ether–hexane) then revealed a more polar product. The mixture was concentrated and repeatedly co-distilled with water and then dissolved in CH₂Cl₂ and concentrated. The residue was purified by chromatography on silica gel and (2:1 ether–hexane) to yield syrupy **6** (450 mg, 87%), $[\alpha]_{\text{D}}^{27} -47$ (*c* 1.4); $\nu_{\text{max}}^{\text{film}}$ 3484 and 3446 (OH), 3082 and 3030 (aromatic), 2102 (N₃), 740 and 697 cm⁻¹ (aromatic). For NMR data, see Tables 1 and 2. Mass spectrum (LSIMS): *m/z* 408.1536 [M⁺+Na] for C₂₀H₂₃N₃NaO₅ 408.1535 (deviation -0.2 ppm).

3.6. 5-Azido-3,4-di-*O*-benzyl-1-*O*-*tert*-butyldiphenylsilyl-5-deoxy- β -D-fructopyranose **7**

To a stirred, ice-water cooled solution of **6** (4.49 g, 11.6 mmol) in dry DMF (30 mL) were added imidazole (840 mg, 12.3 mmol) and *tert*-butylchlorodiphenylsilane (3.2 mL, 12.3 mmol) and the mixture was left at room temperature 12 h. TLC (2:1 ether–hexane) then revealed a less polar product. The mixture was concentrated and the residue dissolved in ether (15 mL) and the resulting solution was washed with brine and concentrated. Column chromatography purification (1:2 ether–hexane) of the residue afforded pure **7** (5.2 g, 72%) as a viscous syrup; $[\alpha]_{\text{D}}^{27} -27$ (*c* 1); $\nu_{\text{max}}^{\text{film}}$ 3469 (OH), 3068 and 3030 (aromatic), 2102 (N₃), 738 and 700 cm⁻¹ (aromatic). For NMR data, see Tables 1 and 2. Mass spectrum (LSIMS): *m/z* 646.2716 [M⁺+Na] for C₃₆H₄₁N₃NaO₅Si 646.2713 (deviation -0.4 ppm).

3.7. Hydrogenation of **7**

Compound **7** (5.18 g, 8.3 mmol) in MeOH (50 mL) was hydrogenated at 50 psi over wet Raney nickel (2.5 g) for 4 h. TLC (ether) then revealed the presence of a slower-running compound (presumably the Δ^2 -pyrroline) together with a non-mobile compound. The hydrogenation was continued for additional 20 h, when TLC (ether) indicated the presence of only the above-mentioned non-mobile compound. The catalyst was removed by filtration and washed with MeOH. The combined filtrate and washings were concentrated to a residue that was submitted to column chromatography (ether with 0.1% Et₃N) to afford (2*R*,3*R*,4*R*,5*R*)-3,4-dibenzyloxy-2'-*O*-*tert*-butyldiphenylsilyl-2,5-bis(hydroxymethyl)pyrrolidine (**1**, 4.6 g, 97%) as a colorless syrup; $[\alpha]_{\text{D}}^{25} +11$ (*c* 1). For NMR data, see Tables 1 and 2. Mass spectrum (LSIMS): *m/z* 604.2854 [M⁺+Na] for C₃₆H₄₃NNaO₄Si 604.2859 (deviation +0.8 ppm).

3.8. *O*-Desilylation of **1**

Compound **1** (86 mg, 0.14 mmol) in THF (3 mL), was treated with a solution of tetra-*n*-butylammonium fluoride trihydrate (70 mg, 0.22 mmol) for 2 h at room temperature. TLC (ether/methanol, 20:1) then showed the presence of a more polar product. The reaction

mixture was concentrated and the residue dissolved in dichloromethane (10 mL) and washed with water. The organic phase was separated and concentrated. Column chromatography [7:1 ether–methanol, 0.1% Et₃N] of the residue yielded crystalline (2*R*,3*R*,4*R*,5*R*)-3,4-dibenzyloxy-2,5-bis(hydroxymethyl)pyrrolidine **8** (30 mg, 56%); mp 80–81°C; $[\alpha]_{\text{D}}^{27} +25$ (*c* 1). For NMR data, see Tables 1 and 2. Anal. calcd for C₂₀H₂₅NO₄: C, 69.94; H, 7.34; N, 4.08. Found: C, 69.70; H, 6.97; N, 4.21%.

3.9. (2*R*,3*R*,4*R*,5*R*)-*N*-Allyl-3,4-dibenzyloxy-2'-*O*-*tert*-butyldiphenylsilyl-2,5-bis(hydroxymethyl)pyrrolidine **1a**

To a solution of **1** (460 mg, 0.8 mmol) in dry acetone (10 mL) was added anhydrous potassium carbonate (540 mg) and the mixture sonicated for 15 min, then allyl bromide (250 μ L, 3 mmol) was added and the mixture was stirring at room temperature. After 12 h TLC (ether) revealed the presence of a less polar compound. The mixture was filtered and the solid thoroughly washed with acetone and the filtrate and washings concentrated to a residue that was partitioned in dichloromethane/water. The organic phase was separated and concentrated to a residue that was submitted to chromatography (1:1 ether–hexane) to give **1a** as a colorless syrup (425 mg, 86%); $[\alpha]_{\text{D}}^{22} +22$ (*c* 1); $\nu_{\text{max}}^{\text{film}}$ 3458 (OH), 3031 and 3020, 736 and 700 cm⁻¹ (aromatic). For NMR data, see Tables 1 and 2. Mass spectrum (LSIMS): *m/z* 644.3170 [M⁺+Na] for C₃₉H₄₇NNaO₄Si 644.3172 (deviation +0.3 ppm).

3.10. (2*R*,3*R*,4*R*,5*R*)-*N*-Benzyl-3,4-dibenzyloxy-2'-*O*-*tert*-butyldiphenylsilyl-2,5-bis(hydroxymethyl)pyrrolidine **1b**

To a solution of **1** (211 mg, 0.36 mmol) in dry acetone (4 mL) was added anhydrous potassium carbonate (250 mg) and the mixture sonicated for 15 min, then benzyl bromide (160 μ L, 1.4 mmol) was added and the mixture was left at room temperature with stirring. After 5 h TLC (2:1 ether–hexane) revealed the presence of a less polar product. The mixture was filtered and the solid thoroughly washed with acetone and the filtrate and washings concentrated to a residue that was submitted to chromatography (1:1 ether–hexane) to give **1b** as a colorless syrup (240 mg, quantitative); $[\alpha]_{\text{D}}^{27} -12$ (*c* 1). For NMR data, see Tables 1 and 2. Mass spectrum (LSIMS): *m/z* HRMS 694.3328 [M⁺+Na] for C₄₃H₄₉NNaO₄Si 694.3329 (deviation +0.1 ppm).

3.11. (2*R*,3*R*,4*R*,5*R*)-3,4-Dibenzyloxy-*N*-*tert*-butyloxy-carbonyl-2'-*O*-*tert*-butyldiphenylsilyl-2,5-bis(hydroxymethyl)pyrrolidine **1c**

To an ice-water cooled, stirred solution of **1** (224 mg, 0.39 mmol) in dry dichloromethane (3 mL), TEA (62 μ L, 0.46 mmol) and di-*tert*-butyl dicarbonate (92 mg, 0.42 mmol) were added and the mixture was left at room temperature. After 5 h TLC (ether) revealed the presence of a faster-running compound. The reaction mixture was quenched with dry methanol (0.3 mL),

then supported on silica gel and chromatographed (1:1 ether–hexane) to afford **1c** (250 mg, quantitative) as a colorless syrup; $[\alpha]_D^{27} -5$ (c 1); $\nu_{\text{max}}^{\text{film}}$ 3441 (OH), 3065 and 3031 (aromatic) 1693 (CO), 737 and 699 cm^{-1} (aromatic). For NMR data, see Tables 1 and 2. Mass spectrum (LSIMS): m/z HRMS 704.3384 [M^+Na] for $\text{C}_{41}\text{H}_{51}\text{NNaO}_6\text{Si}$ 704.3383 (deviation -0.2 ppm).

Acknowledgements

The authors are deeply grateful to Ministerio de Educación y Cultura (Spain) for financial support (Project PB98-1357) and for a grant (F. Franco).

References

- Izquierdo, I.; Plaza, M.-T.; Robles, R.; Franco, F. *Carbohydr. Res.* **2001**, *330*, 401–408.
- Izquierdo, I.; Plaza, M.-T.; Robles, R.; Franco, F. *Tetrahedron: Asymmetry* **2001**, *12*, 2481–2487.
- (a) Kato, A.; Adachi, I.; Miyauchi, M.; Ikeda, K.; Komae, T.; Kizu, H.; Kameda, Y.; Watson, A. A.; Nash, R. J.; Wormald, M. R.; Fleet, G. W. J.; Asano, N. *Carbohydr. Res.* **1999**, *316*, 95–103; (b) Asano, N.; Kuroi, H.; Ikeda, K.; Kizu, H.; Kameda, Y.; Kato, A.; Adachi, I.; Watson, A. A.; Nash, R. J.; Fleet, G. W. J. *Tetrahedron: Asymmetry* **2000**, *11*, 1–8.
- Isolation from natural sources: (a) Evans, S. V.; Fellows, L. E.; Shing, T. K. M.; Fleet, G. W. J. *Phytochemistry* **1985**, *24*, 1953–1956; (b) Asano, N.; Oseki, K.; Kizu, H.; Matsui, K. *J. Med. Chem.* **1994**, *37*, 3701–3706; (c) Watson, A. A.; Nash, R. J.; Wormald, M. R.; Harvey, D. J.; Dealler, S.; et al. *Phytochemistry* **1997**, *46*, 255–260; (d) Asano, N.; Nishida, M.; Kizu, H.; Matsui, K. *J. Nat. Prod.* **1997**, *60*, 98–101; (e) Asano, N.; Kato, A.; Miyauchi, M.; Kizu, H.; Kameda, Y.; et al. *J. Nat. Prod.* **1998**, *61*, 625–628; (f) Kato, A.; Adachi, I.; Miyauchi, M.; Ikeda, K.; Komae, T.; et al. *Carbohydr. Res.* **1999**, *316*, 95–103; (g) Kim, H. S.; Kim, Y. H.; Hong, Y. S.; Paek, M. S.; Lee, H. S.; Kim, T. H.; Kim, K. W.; Lee, J. J. *Planta Med.* **1999**, *65*, 437–439; (h) Ikeda, K.; Takahashi, M.; Nishida, M.; Miyauchi, M.; Kizu, H.; Kameda, Y.; Arisawa, M.; Watson, A. A.; Nash, R. J.; Fleet, G. W. J.; Asano, N. *Carbohydr. Res.* **2000**, *323*, 73–80. For previous syntheses, see: (a) Card, P. J.; Hitz, W. D. *J. Org. Chem.* **1985**, *50*, 891–893; (b) Fleet, G. W. J.; Smith, P. W. *Tetrahedron* **1987**, *43*, 971–978; (c) Hung, R. R.; Straub, J. A.; Whitesides, G. M. *J. Org. Chem.* **1991**, *56*, 3849–3855; (d) Legler, G.; Korth, A.; Berger, A.; Ekhardt, C.; Gradnig, G.; Stütz, A. E. *Carbohydr. Res.* **1993**, *250*, 67–78; (e) Baxter, E. W.; Reitz, A. B. *J. Org. Chem.* **1994**, *59*, 3175–3185; (f) Park, K. H.; Yoon, Y. J.; Lee, S. G. *Tetrahedron Lett.* **1994**, *35*, 9737–9740; (g) Chorghade, M. S.; Cseke, C. T.; Liu, P. S. *Tetrahedron: Asymmetry* **1994**, *5*, 2251–2254; (h) Ikota, N. *Heterocycles* **1995**, *41*, 983–994; (i) Asano, N.; Kizu, H.; Oseki, K.; Tomioka, E.; Matsui, K.; et al. *J. Med. Chem.* **1995**, *38*, 2349–2356; (j) Le Merrer, Y.; Poitout, L.; Depazay, J.-C.; Dosbaa, I.; Geoffroy, S.; Foglietti, M.-J. *Biorg. Med. Chem.* **1997**, *5*, 519–533.
- Garegg, P. J.; Samuelsson, B. *J. Chem. Soc., Perkin 1* **1980**, 2866–2868.
- Tatibouët, A.; Lefoix, M.; Nadolny, J.; Martin, O. R.; Rollin, P.; Yang, J.; Holman, G. D. *Carbohydr. Res.* **2001**, *333*, 327–334. In this paper, compound **3** was mistakenly named with the β -L-sorbo configuration.
- Beaupere, D.; Stasik, B.; Uzan, R.; Demailly, G. *Carbohydr. Res.* **1989**, *191*, 163–166.
- (a) Liu, K. K.-C.; Kajimoto, T.; Chen, L.; Zhong, Z.; Ichikawa, Y.; Wong, C.-H. *J. Org. Chem.* **1991**, *56*, 6280–6289; (b) Kajimoto, T.; Chen, L.; Liu, K. K.-C.; Wong, C.-H. *J. Am. Chem. Soc.* **1991**, *113*, 6678–6680; (c) Takayama, S.; Martin, R.; Wu, J.; Laslo, K.; Siuzdak, G.; Wong, C.-H. *J. Am. Chem. Soc.* **1997**, *119*, 8146–8151.